Theravance Biopharma, Inc. TBPH R2K
Healthcare · Biotechnology · United States
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
READ MORE ›$16.06
+75.33% 1Y
Market & Price
Market Cap
$827.94M
Current Price
$16.06
High / Low (52W)
$20.74 / $9.16
Beta
0.19
Valuation
Stock P/E
7.20
Industry PE
23.65
Forward P/E
12.80
PEG Ratio
-
Book Value
$5.81
Price to Book
2.76
P/S
7.54
EV/EBITDA
72.05
Dividend Yield
-
Profitability & Returns
ROCE
29.45%
ROE
50.17%
ROA
0.76%
Profit Margin
-
Op Margin
-33.05%
EPS (Latest Qtr)
$-0.10
EPS (TTM)
$2.23
Balance Sheet & Liquidity
Debt/Equity
0.14
Quick Ratio
12.91
Current Ratio
13.14
Debt
$40.50M
Total Assets
$485.57M
Current Assets
$418.46M
Working Capital
$380.16M
Ownership
Promoter Holding
4.64%
Chg in Prom Hold
-
FII / Inst Holding
99.20%
Chg in FII Hold
0.03%
Financial Snapshot
Enterprise Value
$473.78M
Total Revenue (TTM)
$109.78M
EBITDA
$6.58M
Free Cash Flow
$22.51M
Operating Cash Flow
$268.78M
Shares Outstanding
51.55M
Gross Margin
71.04%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
27.91%
Profit 5Y
-50.48%
Revenue (YoY)
15.00%
Earnings (YoY)
-
PROS
- Strong return on equity of 50.2%.
- Healthy ROCE of 29.4%.
- Compounding revenue at 27.9% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -50.5% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TBPH Theravance Biopharma, Inc. R2K | 16.06 | 7.20 | $827.94M | - | 29.45% | 50.17% | 27.91% | -50.48% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 3.09M | 3.51M | 4.28M | 4.51M | 8.32M | 23.48M | 12.84M | 15.74M | 5.34M | 26.15M | 12.43M | 29.50M | 19.86M | 15.01M | 18.26M | 18.73M | 14.26M | 12.91M | 13.19M | 14.95M | 13.20M | 11.05M | 12.45M | 14.65M | 10.42M | 13.75M | 15.69M | 17.57M | 14.50M | 14.26M | - | - | 15.39M | 26.20M | 19.99M | 45.89M | 17.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.82M | 28.92M | 26.45M | 25.88M | 23.55M |
| Operating Income | -47.50M | -33.49M | -57.83M | -58.83M | -65.12M | -57.00M | -79.18M | -64.98M | -48.70M | -62.45M | -62.62M | -73.67M | -42.48M | -65.20M | -70.57M | -72.48M | -72.18M | -76.61M | -76.49M | -83.89M | -64.11M | -53.62M | -56.17M | -38.50M | -26.88M | -9.14M | -17.43M | -24.91M | -16.12M | -8.76M | -6.24M | -11.21M | -15.71M | - | - | -14.43M | -2.73M | -6.46M | 20.01M | -5.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.44M | 74.80M | -1.68M | 73.85M | -5.63M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 643.00K | 663.00K | 573.00K | 582.00K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.14M | 73.21M | -2.89M | 73.07M | -6.47M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -559.00K | 18.37M | -6.50M | 12.04M | -1.54M |
| Net Income | -47.23M | -33.96M | -67.33M | -65.32M | -66.29M | -66.88M | -86.92M | -65.09M | -40.82M | -59.43M | -50.19M | -72.58M | -39.84M | -58.43M | -65.61M | -83.05M | -62.89M | -73.64M | -58.43M | -79.68M | -52.41M | -35.31M | -32.03M | -25.95M | -8.19M | 916.63M | -10.36M | -22.09M | -15.64M | -8.95M | -8.51M | -11.66M | -16.53M | - | - | -13.58M | 54.84M | 3.62M | 61.02M | -4.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.40 | -1.00 | -1.16 | -0.92 | -1.24 | -0.80 | -0.48 | -0.43 | -0.34 | -0.11 | 12.14 | -0.15 | -0.35 | -0.28 | -0.17 | -0.17 | -0.24 | -0.34 | - | - | -0.27 | 1.08 | 0.07 | 1.15 | -0.10 |
| R&D Expense | 32.07M | 31.95M | - | 40.56M | 42.93M | 39.34M | - | 47.77M | 48.62M | 52.69M | - | 53.82M | 46.40M | 52.01M | - | 66.01M | 62.40M | 67.37M | - | 67.60M | 51.09M | 43.74M | - | 23.25M | 14.92M | 9.87M | - | 14.57M | 9.43M | 8.31M | - | 8.97M | 9.95M | 9.27M | - | 11.45M | 10.49M | 8.11M | - | 5.83M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 48.65M | 15.39M | 60.37M | 73.41M | 71.86M | - | 51.35M | 57.42M | 64.38M | 107.46M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 130.47M | 110.72M | 106.82M | 111.07M |
| Operating Income | -9.57M | -156.28M | -232.54M | -181.90M | -180.47M | -260.12M | -238.75M | -251.91M | -297.63M | - | -79.12M | -53.29M | -42.44M | -3.60M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -79.42M | -42.66M | -38.45M | 134.52M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 6.37M | 2.35M | 2.55M | 2.46M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -92.81M | -49.27M | -44.61M | 129.25M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 9.00K | 5.92M | 11.80M | 23.35M |
| Net Income | -9.57M | -156.28M | -237.04M | -182.22M | -190.67M | -285.40M | -215.52M | -236.46M | -278.02M | - | 872.13M | -55.19M | -56.42M | 105.89M |
| Diluted EPS | - | - | - | - | - | - | - | -4.25 | -4.46 | - | 11.85 | -1.00 | -1.15 | 2.06 |
| R&D Expense | 114.00M | 120.58M | 168.52M | 129.16M | 141.71M | 173.89M | 201.35M | 219.25M | 260.95M | 193.66M | 63.39M | 40.62M | 37.64M | 37.41M |
Compounded Sales Growth
| 5 Years: | 27.91% |
| 1 Year: | 15.00% |
Compounded Profit Growth
| 5 Years: | -50.48% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +75.33% |
| 6 Months: | -15.21% |
| 3 Months: | -12.00% |
| 1 Month: | -3.66% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 25.18M | - | 337.77M | 300.12M | 639.25M | 441.40M | 560.24M | 408.83M | 469.06M | - | 607.40M | 382.00M | 354.16M | 485.57M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 353.46M | 133.54M | 161.07M | 418.46M |
| Cash & Equivalents | - | 0 | 0 | 277.54M | 89.22M | 112.71M | 344.71M | 88.98M | 378.02M | 58.06M | 81.47M | - | 298.17M | 39.55M | 37.80M | 167.81M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 16.79M | 17.47M | 18.44M | 45.54M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 165.60M | 169.00M | 178.62M | 188.85M |
| Current Liabilities | - | - | 36.85M | - | 41.26M | 49.47M | 49.27M | 62.55M | 98.55M | 111.70M | 123.57M | - | 28.71M | 24.77M | 32.09M | 38.30M |
| Long Term Debt | - | - | - | - | - | - | - | 223.75M | 454.35M | 455.04M | 619.17M | 599.39M | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 52.16M | 49.16M | 49.82M | 42.70M |
| Total Equity | -140.72M | -6.99M | -17.04M | - | 289.79M | 243.06M | 350.23M | 115.18M | -51.59M | -223.84M | -303.75M | - | 441.80M | 213.00M | 175.54M | 296.72M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 65.23M | 48.09M | 49.47M | 51.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -168.86M | -98.99M | -201.05M | -112.87M | -238.20M | -250.40M | - | -186.99M | -27.00M | -11.54M | 238.54M |
| Investing Cash Flow | - | - | - | 111.04M | -148.24M | -56.33M | 176.71M | -83.05M | 10.72M | - | 1.15B | -32.70M | 12.28M | -105.28M |
| Financing Cash Flow | - | - | - | 81.31M | 479.23M | 1.66M | 225.20M | 1.29M | 263.08M | - | -758.81M | -198.93M | -2.50M | -3.25M |
| Capital Expenditure | -2.59M | -2.73M | -3.11M | -2.65M | -2.13M | - | - | - | - | - | -572.00K | -2.49M | -332.00K | -42.00K |
| Free Cash Flow | - | - | - | -171.50M | -101.12M | - | - | - | - | - | -187.56M | -29.48M | -11.87M | 238.50M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 208.21M | -258.63M | -1.75M | 130.01M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 128.83M | 197.05M | 445.00K | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -371.0% | -1,690.6% | -395.5% | -343.1% | -414.2% | - | -154.1% | -92.8% | -65.9% | -3.4% |
| Net Margin % | - | - | - | - | -391.9% | -1,855.0% | -357.0% | -322.1% | -386.9% | - | 1,698.5% | -96.1% | -87.6% | 98.5% |
| ROE % | 137.0% | 917.4% | -81.8% | -75.0% | -54.4% | -247.8% | 417.8% | 105.6% | 91.5% | - | 197.4% | -25.9% | -32.1% | 35.7% |
| ROCE % | - | 1,338.5% | -78.4% | -72.6% | -30.6% | -68.7% | -51.7% | -84.8% | -86.1% | - | -13.7% | -14.9% | -13.2% | -0.8% |
Shareholding Pattern
Insiders
4.64%
Institutions
99.20%
Public Float
104.03%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Madison Avenue Partners, LP | 18.45% | 9.51M | $152.75M |
| 2 | Weiss Asset Management Lp | 14.46% | 7.46M | $119.76M |
| 3 | Newtyn Management, Llc | 9.39% | 4.84M | $77.76M |
| 4 | Blackrock Inc. | 8.33% | 4.30M | $69.00M |
| 5 | Irenic Capital Management LP | 5.36% | 2.76M | $44.34M |
| 6 | Vanguard Capital Management LLC | 3.46% | 1.78M | $28.65M |
| 7 | State Street Corporation | 2.52% | 1.30M | $20.84M |
| 8 | Acadian Asset Management. LLC | 2.48% | 1.28M | $20.50M |
| 9 | Two Sigma Investments, LP | 2.44% | 1.26M | $20.21M |
| 10 | Geode Capital Management, LLC | 2.21% | 1.14M | $18.27M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TBPH
No recent headlines available.